Kymab Group Ltd: Kymab appoints Dr Martin Nicklasson as Non-Executive Chair
(Thomson Reuters ONE) -
Kymab appoints Dr Martin Nicklasson as Non-Executive Chair
Cambridge, UK, 16 June 2017 - Kymab Group Limited ("Kymab"), a leading human
monoclonal antibody biopharmaceutical group, announces the appointment of Dr
Martin Nicklasson as Non-Executive Chair.
Dr.Nicklasson has held a number of senior positions at AstraZeneca Plc including
Executive Vice President ("EVP") of Global Marketing and Business Development
and EVP of Global Drug Development. He was CEO of Biovitrum AB and Swedish
Orphan Biovitrum AB and is currently Chair of the boards of Orexo AB and Zealand
Pharma A/S.
"I am delighted to welcome Martin to Kymab," said Dr David Chiswell, CEO of
Kymab, commenting on the appointment. "As we continue to develop as a company it
is important to be able to attract high calibre individuals who have the global
experience to help Kymab on its journey. Not only has Martin got that experience
but his judgement and personality are ideally suited to helping us prepare for
the next steps in Kymab's growth strategy."
Dr Martin Nicklasson, newly appointed Chair of Kymab added: "Kymab has built an
impressive early stage product pipeline using its Kymouse technology which
provides a world class platform for the discovery of highly selective, potent
therapeutic human monoclonal antibodies. I am pleased to be joining Kymab at
such an exciting time in its growth trajectory and look forward to working with
the CEO Dr. David Chiswell, the Board and the excellent Kymab team focused on
building a substantial global biopharmaceutical business."
Dr.Nicklasson also serves as a board member of Basilea Pharmaceutica Ltd, and
Biocrine AB. He previously served as a board member of Scandinavian Life science
invest AB, Denator AB, Pozen Inc., Oasmia AB, Farma Investment AS, PledPharma
AB, BioInvent International AB, Premier Research Group Ltd. and EffRx
Pharmaceuticals SA. He is a certified pharmacist and holds a PhD in
Pharmaceutical Technology from the Uppsala University, where he is Associate
Professor at the Department of Pharmaceutics.
For further information contact:
Kymab:
David Chiswell, Chief Executive Officer
Anne Hyland, Chief Financial Officer
Tel: +44 (0)1223 833 301, Email: anne.hyland(at)kymab.com
Notes to Editors
About Kymab
Kymab Group Limited ("Kymab") is a leading biopharmaceutical group focused on
the discovery and development of fully human monoclonal antibody drugs using its
proprietary Kymouse(TM) antibody platform.
Kymab has raised over US$220m of equity financing which includes $100m Series C
financing. It has an experienced management team with a successful track record
in drug discovery and development and has numerous therapeutic antibody
programmes in immuno-oncology, auto-immunity, haematology, infectious disease
and other areas.
About Kymouse(TM)
Kymouse(TM) is a transgenic human antibody platform to discover and develop
fully human monoclonal antibody drugs. Work published in Nature Biotechnology
demonstrate that the Kymouse(TM) technology yields an antibody library
constituted from 100 trillion different antibodies. From this deep library, rare
high-quality antibodies can be selected and developed into therapeutics.
Kymouse(TM) has been designed to maximise the diversity of human antibodies
produced in response to immunisation with antigens. Selecting from a broad
diversity of fully human antibodies assures the highest probability of finding
that rare drug candidate with best-in-class characteristics. The Kymouse(TM)
naturally matures these molecules to highly potent drugs obviating the need for
further time-consuming modifications. Kymab is using the platform for its
internal drug discovery programmes and in partnership with pharmaceutical
companies.
For more information please see http://www.kymab.com
Kymab and Kymouse are trademarks of Kymab Limited.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Kymab Group Ltd via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 16.06.2017 - 10:00 Uhr
Sprache: Deutsch
News-ID 548288
Anzahl Zeichen: 4876
contact information:
Town:
Cambridge
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 395 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Kymab Group Ltd: Kymab appoints Dr Martin Nicklasson as Non-Executive Chair"
steht unter der journalistisch-redaktionellen Verantwortung von
Kymab Group Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
